ARCHIVED: Appendix 7a: The Management of the National Antiviral Stockpile: Options Report - Purchase requirements, by jurisdiction, to meet paediatric oseltamivir, zanamivir, and amantadine targets

 

APPENDIX 7a: Purchase requirements, by jurisdiction, to meet paediatric oseltamivir, zanamivir, and amantadine targets1
(costs for purchases, by jurisdiction, were provided to Public Health Network Council)

Notes:

1 2008 Population Estimates:  Total population >1 year of age = 33 million; total paediatric population (1-<12) = 4 million; total adult population (12+) = 29 million

2 P/T Proportions Used: 2008 total population census data

3 There are already approx. 2 million paediatric oseltamivir capsules already in the NAS and distributed to P/Ts on a per capita basis, the table reflects the remaining 7.2 million doses to be purchased.

4 NT adult oseltamivir stock does not expire until 2011.  Options to be discussed with PWGSC in order to meet paediatric targets through Exchange program, etc.

Jurisdiction2 Remaining doses3 paediatric oseltamivir to be purchased Zanamivir paediatric doses Zanamivir adult doses Amantadine doses (additional 10% of NAS)
30 mg capsules 45 mg capsules

NAS

5,923,165

1,247,983

700,000

5,000,000

5,800,000

NL (1.5%)

87,439

20,414

10,673

76,234

88,432

PEI (.4%)

24,233

5,650

2,938

20,987

24,344

NS (2.8%)

162,247

37,979

19,717

140,839

163,373

NB (2.2%)

130,062

30,555

15,704

112,169

130,116

QC (23.3%)

1,348,612

316,832

162,868

1,163,341

1,349,476

ON (38.8%)

2,374,679

414,366

271,688

1,940,627

2,251,127

MB (3.6%)

210,417

49,418

25,384

181,313

210,323

SK (3%)

160,920

36,240

21,350

152,498

176,898

AB (10.8%)

637,638

151,279

75,338

538,126

624,226

BC (13.2%)

768,006

180,894

92,074

657,673

762,901

YK (.1%)

5,885

1,361

696

4,975

5,771

NT (.1%)

7,5144

1,7304

910

6,497

7,536

NU (.1%)

5,512

1,266

661

4,720

5,476

 

Page details

Date modified: